Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: A systematic review

HPB

Volumn 17, Issue 4, 2015, Pages 285-291

  Stevens, Lewis ^a   Pathak, Samir ^a   Nunes, Quentin M ^b   Pandanaboyana, Sanjay ^a   Macutkiewicz, Christian ^a   Smart, Neil ^c   Smith, Andrew M ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; AUTACOID; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CINAHL; CLINICAL DECISION MAKING; COMORBIDITY; EMBASE; HUMAN; MEDLINE; NEUTROPHIL LYMPHOCYTE RATIO; PANCREAS CANCER; PREOPERATIVE PERIOD; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; BLOOD; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE COUNT; MORTALITY; NEUTROPHIL; PANCREATIC NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE COUNT; LYMPHOCYTES; NEUTROPHILS; PANCREATIC NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84924285335     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12355     Document Type: Review

References (47)

1. Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, et al. (2009) Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 100: 246-250.
2. Herszenyi L, Tulassay Z,. (2010) Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14: 249-258.
3. Sobin LH, Gospodarowicz MK, Wittekind C, eds. (2009) International Union Against Cancer. TNM Classification of Malignant Tumours, 7th edn. New York: Wiley-Blackwell, pp. 132-135.
4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. (2009) American Joint Committee on Cancer. Cancer Staging Manual, 7th edn. New York: Springer, pp. 285-296.
5. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. (1995) Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221: 721-731.
6. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al. (2007) Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110: 738-744.
7. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M,. (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27: 324-329.
8. Balkwill F, Mantovani A,. (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
9. Allin KH, Bojesen SE, Nordestgaard BG,. (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27: 2217-2224.
10. Candido J, Hagemann T,. (2013) Cancer-related inflammation. J Clin Immunol 33 (Suppl. 1): S79-S84.
11. Servais C, Erez N,. (2013) From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol 229: 198-207.
12. Coussens LM, Werb Z,. (2002) Inflammation and cancer. Nature 420: 860-867.
13. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, St O'Reilly DJ, et al. (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47: 2633-2641.
14. Du Clos TW,. (2000) Function of C-reactive protein. Ann Med 32: 274-278.
15. Dumitru CA, Lang S, Brandau S,. (2013) Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 23: 141-148.
16. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, et al. (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155: 537-547.
17. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, et al. (2012) Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 12: 399.
18. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K, et al. (2008) Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. 2008. J Surg Oncol 98: 540-544.
19. Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S, et al. (2011) Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers 26: 209-215.
20. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ,. (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107: 695-699.
21. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF. Stojakovic T, Golbeck S, et al. (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108: 901-907.
22. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E,. (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137: 425-428.
23. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ,. (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181-184.
24. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T,. (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238: 197-202.
25. Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS,. (2004) Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 90: 1707-1709.
26. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
27. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. (2013) Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev 2: 71.
28. Hayden JA, van der-Windt DA, Cartwright JL, Côté P, Bombardier C,. (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158: 280-286.
29. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109: 416-421.
30. Hamed MO, Roberts KJ, Smith AM, Morris Stiff G,. (2013) Elevated pre-operative neutrophil to lymphocyte ratio predicts disease free survival following pancreatic resection for peri-ampullary carcinomas. Pancreatology 13: 534-538.
31. La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G,. (2012) The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 19: 2917-2923.
32. Sanjay P, de Figueiredo RS, Leaver H, Ogston S, Kulli C, Polignano FM, et al. (2012) Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP 13: 199-204.
33. Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, et al. (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 18: 2318-2328.
34. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP,. (2011) Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 35: 868-872.
35. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI,. (2010) Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 200: 197-203.
36. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, et al. (2009) Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 35: 605-610.
37. Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW,. (2007) Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 9: 456-460.
38. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, et al. (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 92: 21-23.
39. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G,. (1995) Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73: 374-379.
40. Gan WQ, Man SF, Senthilselvan A, Sin DD,. (2004) Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59: 574-580.
41. Park HS, Park JY, Yu R,. (2005) Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 69: 29-35.
42. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254: 311-319.
43. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13: 1035-1046.
44. Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, et al. (2008) Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg 12: 1068-1073.
45. Springett GM, Hoffe SE,. (2008) Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control 15: 295-307.
46. Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M,. (2007) Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37: 114-120.
47. Krauthamer M, Rouvinov K, Ariad S, Man S, Walfish S, Pinsk I, et al. (2013) A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology 85: 27-32.